Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Printable Datasheet

Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody [rPDL1/4773]

In Stock
Catalog Number Formulation Size Price
29126-MSM13-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
29126-MSM13-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
29126-MSM13-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day
Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody

Formalin-fixed, paraffin-embedded human skin stained with PD-L1 Recombinant Mouse Monoclonal Antibody (rPDL1/4773).

Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody - Image 2

Formalin-fixed, paraffin-embedded human placenta stained with PD-L1 Recombinant Mouse Monoclonal Antibody (rPDL1/4773).

Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody - Image 3

SDS-PAGE Analysis of Purified PD-L1 Recombinant Mouse Monoclonal Antibody (rPDL1/4773). Confirmation of Purity and Integrity of Antibody.

Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody - Image 4

Western Blot Analysis of NIH3T3, PC3 and MCF-7 cell lysates using PD-L1 Mouse Monoclonal Antibody (PDL1/2746).

PD-L1 Antibody in Western Blot (WB)

PD-L1 Antibody in Western Blot (WB)

Western Blot Analysis of A-549 cell lysates using PD-L1 Recombinant Mouse Monoclonal Antibody (rPDL1/4773).

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
IHC Protocol
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes
Western Blot (WB)
2-4ug/ml
Western Blot Protocol

Summary

PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

Product Properties & Targets

Antibody Type
Mouse Monoclonals, Recombinant Mouse Monoclonals
Host
Mouse
Applications
Immunohistochemistry, Western Blot
Species Reactivity
Human
Research Areas
Immunology, Mast Cell Marker, PD-1 blockade immunotherapy, Signal Transduction
Isotype / Light Chain
IgG2a / Kappa
Cellular Localization
Cell membrane, Early endosome membrane, Endomembrane system, Recycling endosome membrane
Gene Name
CD274
Positive Control
A-549, NIH3T3, PC3 or MCF-7 cells. Human placenta, spleen or tonsil tissue.
Immunogen
Recombinant fragment (around aa 39-191) of human CD274 (PD-L1) protein (exact sequence is proprietary)
Alternate Names
Programmed cell death 1 ligand 1, B7 homolog 1, B7 homolog 1; B7-H1; CD274; PD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; Programmed cell death 1 ligand 1

Database Links

Entrez Gene ID
29126
SwissProt
Q9NZQ7

Additional Information

Clone
rPDL1/4773
Chromosome Location
9p24.1
Mol. Weight of Antigen
37-50kDa

Related Antibodies

View All CD274 Antibodies

Functions

  • Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
  • The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

Key References

  • Dong, H., et al. 1999. Nat. Med. 5: 1365-1369.

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK
Call Us Now: 1-866-2-NEOBIO (1-866-263-6246)
NeoBiotechnologies Logo
Company Info
Antibodies
Antibody Validation
Research Areas
Resources
Newsletter Signup Updates & Sales